Blog Layout

The New Backbone of Clinical Trial Design

Dr. Douglas A. Levine


2012: Most scientists would now agree that The Cancer Genome Atlas (TCGA) is a transformative program in cancer biology, at least in defining the genomic landscape for a variety of malignancies in a reliable and robust manner. Research begets research and TCGA is no exception. On a computational level, there has been relatively little exploitation of the available germline data to examine quantitative trait loci (QTLs), and on the biologic level, there has been a lack of proteomic integration with TCGA – except for the recent inclusion of the reverse phase protein arrays on available residual material. Even the most nascent scientist can imagine countless additional outstanding analyses to be performed with TCGA data. 


A major contribution that TCGA has made to date is in the design of molecularly targeted clinical trials.  Prior to the widespread availability of reference genomic data, clinical trials of targeted therapeutics were based on a comprehensive review of the limited literature, generally indicating specific genomic events identified in a relatively small and sometimes non-uniform patient population. With TCGA’s data, now the starting point is often a survey of relevant events in the specified disease. As characterizations of more cancer types are completed, similarities and differences in event types for a given pathway or target can be highlighted across varied tumors types. For example, breast, endometrial, and colon cancers have many somatic mutations in the PIK3CA and PTEN genes. However, in ovarian cancer, copy number alterations in these genes predominate, and in lung squamous cell carcinoma, there is a plethora of amplification events in PIK3CA and mixed mutation and somatic copy number alterations (SCNAs) in PTEN. These varied genomic differences can now be (and are) considered when planning clinical trials. 


MK-2206 is a selective allosteric inhibitor of AKT and is equally potent against AKT1 and AKT2, but less so against AKT3. MK-2206 inhibits phosphorylation of AKT1/2, which is a likely consequence of PI3K pathway activation through varied mechanisms, including PTEN or INPP4B loss, mutation in PIK3CA, PIK3R1, or AKT, and activation by other receptor tyrosine kinases. The PI3K Stand Up to Cancer Dream Team has recently opened two clinical trials in ovarian and endometrial cancers using MK-2206 as monotherapy in patients with recurrent disease. In designing these trials, TCGA’s data regarding the genomic heterogeneity have played a key role. It has been well known for many years that endometrial tumors have frequent somatic mutations in PTEN, PIK3CA, and other pathway members. However, for high-grade serous ovarian cancer, TCGA has identified activation of the PI3K/AKT pathway in approximately 40 percent of cases, mostly through SCNA and not through somatic mutation. Based on these genomic data, the endometrial trial is accruing ‘all-comers’ and stratifying them to treatment arms based on the results of a patient’s PIK3CA mutation testing. The ovarian trial is restricted to patients with an event in the PI3K/AKT pathway evidenced by either prior mutation detection, which is unlikely, or through PTEN loss as measured by immunohistochemistry (IHC). This loss is expected to be identified in approximately 20 percent of cases (unpublished data). The TCGA ovarian data directly informed this trial design. In contrast to mutational event testing for the PI3K/AKT pathway, which is becoming increasingly available in many CLIA-compliant laboratories, SCNA assays are hard to develop for patient selection on clinical trials. IHC is a widely available assay that can be applied to PTEN at academic centers with potential trial patients. Both trials will have sufficient correlative studies to survey all major events within the PI3K/AKT pathway once patient accrual is complete. Similar patient inclusion criteria could not be used for the same drug being tested in two different diseases due to the heterogeneous genomic background.

This example of the integration of TCGA data is just one of several with similar merit that could have been discussed. I believe that in the future of clinical trial design for targeted agents, after established pre-clinical biology, we will begin to search for a disease with sufficient genomic events to make a clinical trial worthwhile. TCGA will continue to play a major role in defining appropriate diseases for targeted agents. I hope to see genomics-directed trials that are somewhat agnostic to tumor site of origin after further proof of principle studies help to turn this admirable goal into reality. 


Trials mentioned in this article:


PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer - NCT01312753


MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer - NCT01283035


Share this Article with others

08 Mar, 2024
The aims of our case-control study were (1) to develop an automated 3-dimensional (3D) Convolutional Neural Network (CNN) for detection of pancreatic ductal adenocarcinoma (PDA) on diagnostic computed tomography scans (CTs), (2) evaluate its generalizability on multi-institutional public data sets, (3) its utility as a potential screening tool using a simulated cohort with high pretest probability, and (4) its ability to detect visually occult preinvasive cancer on prediagnostic CTs.
08 Mar, 2024
Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
08 Mar, 2024
International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international cancer registry collecting data from 19 cancer centers, makes data from >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional real-world longitudinal clinical data, including treatment and outcome data, are being collected by the AACR Project GENIE Biopharma Collaborative using the PRISSMM data curation model. Several thousand of these cases are now also available in cBioPortal. We have significantly enhanced the functionalities of cBioPortal to support the visualization and analysis of this rich clinico-genomic linked dataset, as well as datasets generated by other centers and consortia. Examples of these enhancements include (i) visualization of the longitudinal clinical and genomic data at the patient level, including timelines for diagnoses, treatments, and outcomes; (ii) the ability to select samples based on treatment status, facilitating a comparison of molecular and clinical attributes between samples before and after a specific treatment; and (iii) survival analysis estimates based on individual treatment regimens received. Together, these features provide cBioPortal users with a toolkit to interactively investigate complex clinico-genomic data to generate hypotheses and make discoveries about the impact of specific genomic variants on prognosis and therapeutic sensitivities in cancer.
08 Mar, 2024
The majority of disease-associated variants identified through genome-wide association studies are located outside of protein-coding regions. Prioritizing candidate regulatory variants and gene targets to identify potential biological mechanisms for further functional experiments can be challenging. To address this challenge, we developed FORGEdb, a standalone and web-based tool that integrates multiple datasets, delivering information on associated regulatory elements, transcription factor binding sites, and target genes for over 37 million variants. FORGEdb scores provide researchers with a quantitative assessment of the relative importance of each variant for targeted functional experiments.
By Bo Zhang 08 Mar, 2024
Cancer is a leading cause of morbidity and mortality worldwide. While progress has been made in the diagnosis, prognosis, and treatment of cancer patients, individualized and data-driven care remains a challenge. Artificial intelligence (AI), which is used to predict and automate many cancers, has emerged as a promising option for improving healthcare accuracy and patient outcomes. AI applications in oncology include risk assessment, early diagnosis, patient prognosis estimation, and treatment selection based on deep knowledge. Machine learning (ML), a subset of AI that enables computers to learn from training data, has been highly effective at predicting various types of cancer, including breast, brain, lung, liver, and prostate cancer. In fact, AI and ML have demonstrated greater accuracy in predicting cancer than clinicians. These technologies also have the potential to improve the diagnosis, prognosis, and quality of life of patients with various illnesses, not just cancer. Therefore, it is important to improve current AI and ML technologies and to develop new programs to benefit patients. This article examines the use of AI and ML algorithms in cancer prediction, including their current applications, limitations, and future prospects. Lead Author: Bo Zhang
By Claudio Luchini 08 Mar, 2024
Artificial intelligence (AI) is concretely reshaping the landscape and horizons of oncology, opening new important opportunities for improving the management of cancer patients. Analysing the AI-based devices that have already obtained the official approval by the Federal Drug Administration (FDA), here we show that cancer diagnostics is the oncology-related area in which AI is already entered with the largest impact into clinical practice. Furthermore, breast, lung and prostate cancers represent the specific cancer types that now are experiencing more advantages from AI-based devices. The future perspectives of AI in oncology are discussed: the creation of multidisciplinary platforms, the comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the ‘AI-revolution’ in oncology. First Author: Claudio Luchini,
By Panayiotis Petousis, PhD 08 Mar, 2024
In the United States, end-stage kidney disease (ESKD) is responsible for high mortality and significant healthcare costs, with the number of cases sharply increasing in the past 2 decades. In this study, we aimed to reduce these impacts by developing an ESKD model for predicting its occurrence in a 2-year period.  Lead Author: Panayiotis Petousis, PhD
By Evan D. Muse 08 Mar, 2024
Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management Lead Author: Evan D. Muse
By Danielle S. Bitterman, MD 08 Mar, 2024
Current status and future applications of LLMs for cancer symptom management and call for cross-disciplinary collaboration that centers the needs of patients and caregivers L ead Author: Danielle S. Bitterman, MD
01 Mar, 2023
New computer systems aim to peer inside our heads—and to help us fix what they find there In the nineteen-sixties, Joseph Weizenbaum, a computer scientist at M.I.T., created a computer program called Eliza. It was designed to simulate Rogerian therapy, in which the patient directs the conversation and the therapist often repeats her language back to her: U ser : My boyfriend made me come here. E liza : Your boyfriend made you come here. U ser : He says I’m depressed much of the time. E liza : I am sorry to hear you are depressed. U ser : It’s true. I am unhappy. E liza : Do you think coming here will help you not to be unhappy? Weizenbaum made Eliza as satire. He doubted that computers could simulate meaningful human interaction. He was alarmed, therefore, when many people who tried the program found it both useful and captivating. His own secretary asked him to leave the room so that she could spend time alone with Eliza. Worse, doctors saw it as a potentially transformative tool. “Several hundred patients an hour could be handled by a computer system designed for this purpose,” three psychiatrists wrote in The Journal of Nervous and Mental Disease, in 1966. “The human therapist, involved in the design and operation of this system, would not be replaced, but would become a much more efficient man since his efforts would no longer be limited to the one-to-one patient-therapist ratio as now exists.” Weizenbaum became an outspoken critic of artificial intelligence. “But the genie was out of the bottle,” Brian Christian, who chronicled the episode in his book “The Most Human Human,” told me. A few years later, a Stanford psychiatrist named Kenneth Colby created Parry, a program that attempted to simulate the language of a person with paranoid schizophrenia, to train students before they cared for real patients. Psychiatrists given transcripts of therapy sessions often couldn’t tell the difference between Parry and humans; in this narrow sense, the chatbot passed the Turing test. In 1972, Parry and Eliza met up for a therapy session: P arry : Do you know anything about bookies? E liza : What makes you think I know anything about bookies? P arry : A bookie didn’t pay me off once. E liza : What does that suggest to you? P arry : I beat up the bookie who did not pay off, and I thought he might use his friends in the underworld to get even with me.  Over time, programmers developed Jabberwacky, Dr. Sbaitso, and alice (the Artificial Linguistic Internet Computer Entity). Exchanges with these chatbots were often engaging, sometimes comical, and occasionally nonsensical. But the idea that computers could serve as human confidants, expanding therapy’s reach beyond the limits of its overworked practitioners, persisted through the decades. In 2017, Alison Darcy, a clinical research psychologist at Stanford, founded Woebot, a company that provides automated mental-health support through a smartphone app. Its approach is based on cognitive behavioral therapy, or C.B.T.—a treatment that aims to change patterns in people’s thinking. The app uses a form of artificial intelligence called natural language processing to interpret what users say, guiding them through sequences of pre-written responses that spur them to consider how their minds could work differently. When Darcy was in graduate school, she treated dozens of hospitalized patients using C.B.T.; many experienced striking improvements but relapsed after they left the hospital. C.B.T. is “best done in small quantities over and over and over again,” she told me. In the analog world, that sort of consistent, ongoing care is hard to find: more than half of U.S. counties don’t have a single psychiatrist, and, last year, a survey conducted by the American Psychological Association found that sixty per cent of mental-health practitioners don’t have openings for new patients. “No therapist can be there with you all day, every day,” Darcy said. Although the company employs only about a hundred people, it has counseled nearly a million and a half, the majority of whom live in areas with a shortage of mental-health providers. Link to original article on The New Yorker
Share by: